JP6609556B2 - 転移がんの治療および予防のための医薬組成物および方法 - Google Patents

転移がんの治療および予防のための医薬組成物および方法 Download PDF

Info

Publication number
JP6609556B2
JP6609556B2 JP2016536543A JP2016536543A JP6609556B2 JP 6609556 B2 JP6609556 B2 JP 6609556B2 JP 2016536543 A JP2016536543 A JP 2016536543A JP 2016536543 A JP2016536543 A JP 2016536543A JP 6609556 B2 JP6609556 B2 JP 6609556B2
Authority
JP
Japan
Prior art keywords
cancer
amino acid
seq
acid sequence
peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2016536543A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017505755A (ja
JP2017505755A5 (enExample
Inventor
デヴェリー、ヨーラム
サンドラー、ウジエル
Original Assignee
イミューン システム キー リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by イミューン システム キー リミテッド filed Critical イミューン システム キー リミテッド
Publication of JP2017505755A publication Critical patent/JP2017505755A/ja
Publication of JP2017505755A5 publication Critical patent/JP2017505755A5/ja
Application granted granted Critical
Publication of JP6609556B2 publication Critical patent/JP6609556B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
JP2016536543A 2013-12-05 2014-12-04 転移がんの治療および予防のための医薬組成物および方法 Active JP6609556B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361912156P 2013-12-05 2013-12-05
US61/912,156 2013-12-05
PCT/IL2014/051058 WO2015083167A1 (en) 2013-12-05 2014-12-04 Pharmaceutical compositions and methods for the treatment and prevention of metastatic cancer

Publications (3)

Publication Number Publication Date
JP2017505755A JP2017505755A (ja) 2017-02-23
JP2017505755A5 JP2017505755A5 (enExample) 2017-12-14
JP6609556B2 true JP6609556B2 (ja) 2019-11-20

Family

ID=52292983

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016536543A Active JP6609556B2 (ja) 2013-12-05 2014-12-04 転移がんの治療および予防のための医薬組成物および方法

Country Status (11)

Country Link
US (1) US9878015B2 (enExample)
EP (1) EP3076988B1 (enExample)
JP (1) JP6609556B2 (enExample)
KR (1) KR102384795B1 (enExample)
CN (1) CN105939724B (enExample)
AU (1) AU2014358671B2 (enExample)
CA (1) CA2931023C (enExample)
DK (1) DK3076988T3 (enExample)
ES (1) ES2742856T3 (enExample)
IL (1) IL245998B (enExample)
WO (1) WO2015083167A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2018130764A (ru) * 2016-02-04 2020-03-04 Имьюн Систем Ки Лтд. Стресс эндоплазматического ретикулума как прогностический инструмент в терапии рака и комбинированная терапия для лечения рака
KR20250009999A (ko) * 2022-05-27 2025-01-20 주식회사 진큐어 신규 펩타이드 및 그의 용도
WO2024228200A1 (en) * 2023-05-03 2024-11-07 Immune System Key Ltd. Cyclic d-peptides, derivatives, compositions and uses thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101310511B1 (ko) * 2004-10-25 2013-09-25 임뮨 시스템 키 리미티드 흉선-특이성 단백질
WO2007091240A2 (en) 2006-02-06 2007-08-16 Immune System Key Ltd. Treatment of immunological diseases
WO2007122622A1 (en) 2006-04-24 2007-11-01 Immune System Key Ltd. Method of treatment of a disease
US20100204097A1 (en) 2006-12-18 2010-08-12 Immune System Key Ltd. Therapeutic methods using a thymus peptide

Also Published As

Publication number Publication date
CA2931023A1 (en) 2015-06-11
IL245998A0 (en) 2016-07-31
US9878015B2 (en) 2018-01-30
EP3076988A1 (en) 2016-10-12
DK3076988T3 (da) 2019-09-16
KR102384795B1 (ko) 2022-04-08
CN105939724B (zh) 2020-01-14
AU2014358671B2 (en) 2019-09-12
AU2014358671A1 (en) 2016-06-02
CN105939724A (zh) 2016-09-14
EP3076988B1 (en) 2019-06-05
IL245998B (en) 2019-12-31
KR20160085361A (ko) 2016-07-15
WO2015083167A1 (en) 2015-06-11
JP2017505755A (ja) 2017-02-23
US20160303200A1 (en) 2016-10-20
CA2931023C (en) 2023-12-19
ES2742856T3 (es) 2020-02-17

Similar Documents

Publication Publication Date Title
US11981754B2 (en) Biomimetic peptide and biodegradable delivery platform for the treatment of angiogenesis- and lymphangiogenesis-dependent diseases
JP6921755B2 (ja) 脳腫瘍幹細胞の成長、遊走および浸潤性を低下させ脳腫瘍患者の生存率を改善する方法および組成物
US20240108686A1 (en) DPEP-1 Binding Compositions and Methods of Use
JP6104872B2 (ja) 細胞取込を最適化するための抗分泌性因子（ａｆ）の使用
JP2022544481A (ja) ポリペプチドまたはその誘導体の応用
JP6609556B2 (ja) 転移がんの治療および予防のための医薬組成物および方法
US20240408071A1 (en) Novel combination of serotonin receptor (5-htr2b) antagonist and an immunomodulator and chemotherapeutic drugs for inhibition of cancer
EP2831093A1 (en) Egfl7 targeting and/or binding polypeptides and methods for inhibiting angiogenesis
WO2020081528A1 (en) Method and system for treating cancer utilizing tinagl 1
KR20190064562A (ko) Mena 단백질 이소형 키나제를 표적화하는 항암 요법을 위한 방법 및 조성물
CN115838436A (zh) 靶向ITGβ5-14-3-3ζ复合物的抗肿瘤多肽B5-X及其制备方法与用途
HK1229242A1 (en) Pharmaceutical compositions and methods for the treatment and prevention of metastatic cancer
HK1229242B (en) Pharmaceutical compositions and methods for the treatment and prevention of metastatic cancer
Isorna et al. Role of Substance P and Neurokinin-1 Receptor System in Thyroid Cancer: New Targets for Cancer Treatment
WO2025068426A1 (en) Treatment of cancers associated with beta-catenin
KR102119197B1 (ko) 세포에서의 자가포식작용 억제용 조성물, 및 이를 포함하는 종양성 질환의 예방 또는 치료용, 또는 항암제 내성 억제용 약학적 조성물
JP2019512669A (ja) 癌治療における予測的ツールとしての小胞体ストレスおよび癌の治療用の併用療法
KR20230120585A (ko) c-MET의 에피토프 및 HIF1α의 에피토프를 포함하는 암 백신 및 이의 용도
WO2020234239A1 (en) A pharmaceutically active substance
HK40022338A (en) A biomimetic peptide and biodegradable delivery platform

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171101

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20171101

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20180718

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180726

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181025

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190320

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190618

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20191002

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20191028

R150 Certificate of patent or registration of utility model

Ref document number: 6609556

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250